DEXMEDETOMIDINE HYDROCHLORIDE INJECTION SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE)

Pieejams no:

JUNO PHARMACEUTICALS CORP.

ATĶ kods:

N05CM18

SNN (starptautisko nepatentēto nosaukumu):

DEXMEDETOMIDINE

Deva:

200MCG

Zāļu forma:

SOLUTION

Kompozīcija:

DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) 200MCG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Ārstniecības joma:

MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS

Produktu pārskats:

Active ingredient group (AIG) number: 0152679004; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2019-04-12

Produkta apraksts

_Dexmedetomidine Hydrochloride Injection _
_Page 1 of 34 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DEXMEDETOMIDINE HYDROCHLORIDE INJECTION
Solution, 4 mcg/mL dexmedetomidine (as dexmedetomidine hydrochloride),
intravenous infusion
(Ready to use, 50 mL and 100 mL vials)
Alpha2-adrenergic agonist
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, ON L5N 2X7
Date of Initial Authorization:
April 12, 2019
Date of Revision:
October 12, 2023
Submission Control Number: 274740
_Dexmedetomidine Hydrochloride Injection _
_Page 2 of 34 _
RECENT MAJOR LABEL CHANGES
4.1 Dosing Considerations
10/2023
7.0 Warnings and Precautions
10/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
...........................................................................................................................
4
1.1
Pediatrics
.................................................................................................................................
4
1.2
Geriatrics
.................................................................................................................................
4
2
CONTRAINDICATIONS
..............................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................................
4
4.1
Dosing Considerations
.............................................................................................................
5
4.2
Recommended Dose and Dosage Adjust